Amedeo's Top 20

Amedeo Smart

Independent Medical Education

30 September 2019

Multidisciplinary Journal Club

  1. Agarwal R, Rossignol P, Romero A, Garza D, et al.
    Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet 2019.

  1. Makrides M, Best K, Yelland L, McPhee A, et al.
    A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery.
    N Engl J Med 2019;381:1035-1045.

  2. Criner GJ, Celli BR, Brightling CE, Agusti A, et al.
    Benralizumab for the Prevention of COPD Exacerbations.
    N Engl J Med 2019;381:1023-1034.

  3. Lange C, Dheda K, Chesov D, Mandalakas AM, et al.
    Management of drug-resistant tuberculosis.
    Lancet 2019;394:953-966.

  4. Maertens J, Cordonnier C, Jaksch P, Poire X, et al.
    Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    N Engl J Med 2019;381:1136-1147.

  1. Roumie CL, Chipman J, Min JY, Hackstadt AJ, et al.
    Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
    JAMA 2019.

  2. Clements O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al.
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol 2019.

  3. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, et al.
    Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    N Engl J Med 2019.

  4. Pasternak B, Ueda P, Eliasson B, Svensson AM, et al.
    Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    BMJ 2019;366:l4772.

  5. Reuter A, Hughes J, Furin J.
    Challenges and controversies in childhood tuberculosis.
    Lancet 2019;394:967-978.

  1. Carvalho AF, Heilig M, Perez A, Probst C, et al.
    Alcohol use disorders.
    Lancet 2019;394:781-792.

  2. Marston NA, Giugliano RP, Im K, Silverman MG, et al.
    Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Circulation 2019.

  3. Munoz D, Uzoije P, Reynolds C, Miller R, et al.
    Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    N Engl J Med 2019;381:1114-1123.

  4. Patel P, Bush T, Conley L, Unger ER, et al.
    Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study.
    J Infect Dis 2019.

  5. .
    Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.
    Lancet 2019.

  1. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, et al.
    Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Diabetes Care 2019.

  2. Hilton LK, Tang J, Ben-Neriah S, Alcaide M, et al.
    --The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
    Blood 2019.

  3. Gelpi M, Ueland PM, Troseid M, Mocroft A, et al.
    Abdominal adipose tissue is associated with alterations in tryptophan-kynurenine metabolism and markers of systemic inflammation in people with HIV.
    J Infect Dis 2019.

  4. Beck RW, Bergenstal RM, Laffel LM, Pickup JC, et al.
    Advances in technology for management of type 1 diabetes.
    Lancet 2019.

  5. Guan H, Morais NAOES, Stuart J, Ahmadi S, et al.
    Discordance of Serological and Sonographic Markers for Hashimoto's Thyroiditis with Gold Standard Histopathology.
    Eur J Endocrinol 2019.


more..

Privacy Policy